Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00504335
Status:
COMPLETED
Last Update Posted:
2015-03-17
First Post:
2007-07-19
Brief Title:
Safety and Pharmacokinetic Study of BIO 300 Capsules
Sponsor:
Humanetics Corporation
Organization:
Humanetics Corporation
Study Overview
Official Title:
A Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profiles of BIO 300 Capsules in Healthy Male and Female Volunteers
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers BIO 300 is expected to be safe for use starting at 500 mg
Detailed Description:
This clinical trial will assess the safety and PK of BIO 300 capsules at doses expected to deliver a radioprotective or therapeutic effect in humans Humanetics is planning to conduct this Phase I single dose dose-escalation 500 1000 1500 and 2000 milligrams study of the safety tolerability and pharmacokinetics of BIO 300 by recruiting approximately 24 healthy men and women between the ages of 18 and 64 to be enrolled in cohorts of 6 subjects per group The first cohort will receive one 500 mg BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting at a clinic skilled in this type of Phase I trial Blood samples will be analyzed for BIO 300 levels hematology chemistry lipid profiles phosphorus clotting factors and fibrinogen as well as pancreatic lipase and amylase Urinalysis will assess kidney function as well as creatinine clearance and BIO 300 clearance All subjects will be monitored for adverse events and the safety of BIO 300 capsules will be evaluated in this setting After review of all safety information and provided no clinically significant negative findings are revealed the second cohort will be treated with 1000mg BIO 300 two 500mg capsules using the same PK sampling program Again safety concerns will be reviewed and provided no clinically significant negative findings are revealed the third and fourth cohort will be treated with 1500 and 2000 mg respectively of BIO 300 using the same PK sampling program
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None